Form 4: AN2 Therapeutics Director Acquires Shares
Insider Transaction Report
AN2 Therapeutics director Gilbert Lynn Marks received 10,367 shares of common stock as non-cash compensation, increasing his direct beneficial ownership to 63,749 shares.
Summary
- Gilbert Lynn Marks, a Director of AN2 Therapeutics, Inc. (ANTX), acquired 10,367 shares of common stock.
- The transaction occurred on October 10, 2025, and was reported on October 13, 2025.
- These shares were issued in lieu of cash compensation under the issuer's non-employee director compensation policy.
- All acquired shares vested immediately upon issuance.
- Following this transaction, Gilbert Lynn Marks directly beneficially owns a total of 63,749 shares of AN2 Therapeutics common stock.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive as a director's beneficial ownership increased, indicating continued alignment with shareholder interests, even though it was compensation rather than a direct purchase.
Positives
- The director's beneficial ownership in the company increased by 10,367 shares, aligning his interests further with shareholders.
- The shares were issued as compensation and vested immediately, indicating a clear and immediate stake for the director.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Gilbert Lynn Marks, a director, received 10,367 shares of common stock from AN2 Therapeutics, Inc. as non-cash compensation under the company's director compensation policy.
Stakeholder Impact
- Shareholders: Increased director ownership can be seen as a positive signal, aligning management's interests with long-term shareholder value.
Key Dates
| Date | Description |
|---|---|
| 10/10/2025 | Date of transaction where shares were acquired by Gilbert Lynn Marks. |
| 10/13/2025 | Date the Form 4 filing was signed and submitted to the SEC. |
Recommendation
holdThe transaction represents routine non-cash compensation for a director, increasing their beneficial ownership. While positive for aligning interests, it does not provide new fundamental information to alter an investment thesis, thus a 'hold' recommendation is appropriate.
Keywords
AN2 Therapeutics, ANTX, Gilbert Lynn Marks, Form 4, Insider Transaction, Director Compensation, Stock Grant, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.